
The FDA has approved givinostat, the first non-steroidal therapy for Duchenne muscular dystrophy, and the drug is now under review for marketing authorization in Europe, where it could represent a significant milestone in the treatment of this debilitating condition.


coremsg

With FDA approval secured, medical drug authorities in the United Kingdom and Europe are now reviewing data on Italian-manufactured givinostat.

Europe Awaits Decision on New Duchenne Drug

approval-of-givinostat-the-first-non-steroidal-therapy-for-duchenne-muscular-dystrophy-awaits-decision-in-europe


Approval of Givinostat, the First Non-Steroidal Therapy for Duchenne Muscular Dystrophy, Awaits Decision in Europe
